Norman E. Lepor

Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events

Jennifer G. Robinson, Michel Farnier, Michel Krempf et al. · New England Journal of Medicine · 2015 · 2.3K citations · Full text

Fenoldopam Mesylate for the Prevention of Contrast-Induced Nephropathy

Gregg W. Stone, Peter A. McCullough, James A. Tumlin et al. · JAMA · 2003 · 407 citations

Efficacy and safety of bempedoic acid added to ezetimibe in statin-intolerant patients with hypercholesterolemia: A randomized, placebo-controlled study

Christie M. Ballantyne, Maciej Banach, G.B. John Mancini et al. · Atherosclerosis · 2018 · 402 citations

Efficacy and Safety of Alirocumab 150 mg Every 4 Weeks in Patients With Hypercholesterolemia Not on Statin Therapy: The ODYSSEY CHOICE II Study

Erik S.G. Stroes, John R. Guyton, Norman E. Lepor et al. · Journal of the American Heart Association · 2016 · 100 citations · Full text

Pharmacokinetics and pharmacodynamics of Abelacimab (MAA868), a novel dual inhibitor of Factor XI and Factor XIa

B. Alexander Yi, Debra Freedholm, Nancy Widener et al. · Journal of Thrombosis and Haemostasis · 2021 · 92 citations · Full text